Use of glycated CD59 levels to assess glycemic control in diabetic patients

Summary The invention enables rapid detection of impaired glucose tolerance (IGT, or “pre-diabetes”) without oral glucose tolerance testing and permits identification of a population at risk of developing the vascular complications associated with diabetes. It also offers a robust tool for monitoring disease progression as the glycation of CD59 is directly linked to the pathophysiology of disease. As such, detection of glycated CD59 represents a significant advance in the detection, monitoring and prediction of vascular sequelae associated with diabetes. Moreover, glycated CD59 can be detected in urine thereby providing patients and doctors a convenient, non-invasive test with greater sensitivity and disease relevance than current measures of diabetes or pre-diabetes.

Applications Diabetes mellitus affects about 16 million Americans. The incidence of type-2 diabetes in the U.S. has increased by 54% over the past seven years, prompting its recognition as a public health crisis that has reached epidemic proportions:
• An estimated 50 million Americans suffer IGT, but there is no simple screening test to identify this “at risk” population.
• Impaired glucose tolerance (IGT, also described as “pre-diabetes”) can triple an individual’s risk of mortality from cardiovascular disease.
• Sixty percent of individuals with diabetes (types 1 and 2) will develop micro- and macrovascular complications.
• Diabetic vascular complications are the leading cause of renal transplants, blindness and limb amputations in adults, consuming close to 15% of the total U.S. healthcare budget. For Further Information Please Contact the Director of Business Development Alex Szidon Email: alex_szidon@harvard.edu Telephone: (617) 495-3067

Inventor(s): Halperin, Jose A.

Type of Offer: Licensing



Next Patent »
« More Diagnostic Patents

Share on      


CrowdSell Your Patent